These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 28943585

  • 1. The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.
    Kogiso T, Kobayashi M, Yamamoto K, Ikarashi Y, Kodama K, Taniai M, Torii N, Hashimoto E, Tokushige K.
    Intern Med; 2017 Nov 15; 56(22):2993-3001. PubMed ID: 28943585
    [Abstract] [Full Text] [Related]

  • 2. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.
    Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H.
    Intern Med; 2018 Sep 01; 57(17):2451-2458. PubMed ID: 29607963
    [Abstract] [Full Text] [Related]

  • 3. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
    Wang S, Zhang X, Han T, Xie W, Li Y, Ma H, Liebe R, Weng H, Ding HG.
    BMC Gastroenterol; 2018 Sep 04; 18(1):137. PubMed ID: 30180806
    [Abstract] [Full Text] [Related]

  • 4. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study.
    Jia JD, Xie W, Ding HG, Mao H, Guo H, Li Y, Wang X, Wang JF, Lu W, Li CZ, Mao Y, Wang GQ, Gao YQ, Wang B, Zhang Q, Ge Y, Wong VW.
    Ann Hepatol; 2017 Sep 04; 16(1):123-132. PubMed ID: 28051801
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.
    Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG.
    World J Gastroenterol; 2014 Aug 28; 20(32):11400-5. PubMed ID: 25170228
    [Abstract] [Full Text] [Related]

  • 6. Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis.
    Ahluwalia V, Heuman DM, Feldman G, Wade JB, Thacker LR, Gavis E, Gilles H, Unser A, White MB, Bajaj JS.
    J Hepatol; 2015 Jan 28; 62(1):75-82. PubMed ID: 25111174
    [Abstract] [Full Text] [Related]

  • 7. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
    Komiyama Y, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Yasui Y, Tamaki N, Takada H, Higuchi M, Gotou T, Kubota Y, Takaura K, Hayashi T, Oh W, Okada M, Enomoto N, Izumi N.
    PLoS One; 2017 Jan 28; 12(3):e0174649. PubMed ID: 28362879
    [Abstract] [Full Text] [Related]

  • 8. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
    Cárdenas A, Ginès P, Marotta P, Czerwiec F, Oyuang J, Guevara M, Afdhal NH.
    J Hepatol; 2012 Mar 28; 56(3):571-8. PubMed ID: 22027579
    [Abstract] [Full Text] [Related]

  • 9. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ, Ahmad F, Blais JD, Chiodo J, Zhou W, Glaser LA, Czerwiec FS.
    Cancer Med; 2017 Apr 28; 6(4):723-729. PubMed ID: 28251822
    [Abstract] [Full Text] [Related]

  • 10. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist.
    Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H, Hatano M, Yao A, Komuro I.
    Int Heart J; 2014 Apr 28; 55(2):131-7. PubMed ID: 24632953
    [Abstract] [Full Text] [Related]

  • 11. Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience.
    Pose E, Solà E, Piano S, Gola E, Graupera I, Guevara M, Cárdenas A, Angeli P, Ginès P.
    Am J Med; 2017 Mar 28; 130(3):372-375. PubMed ID: 27746291
    [Abstract] [Full Text] [Related]

  • 12. Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT).
    Verbalis JG, Ellison H, Hobart M, Krasa H, Ouyang J, Czerwiec FS, Investigation of the Neurocognitive Impact of Sodium Improvement in Geriatric Hyponatremia: Efficacy and Safety of Tolvaptan (INSIGHT) Investigators.
    Am J Kidney Dis; 2016 Jun 28; 67(6):893-901. PubMed ID: 26874645
    [Abstract] [Full Text] [Related]

  • 13. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH, Bohm NM, Nemecek BD, Crawford R, Kelley D, Bhasin B, Nietert PJ, Velez JCQ.
    Am J Kidney Dis; 2018 Jun 28; 71(6):772-782. PubMed ID: 29478867
    [Abstract] [Full Text] [Related]

  • 14. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Tajiri K, Tokimitsu Y, Ito H, Atarashi Y, Kawai K, Minemura M, Yasumura S, Takahara T, Shimizu Y, Sugiyama T.
    Dig Dis; 2018 Jun 28; 36(4):314-321. PubMed ID: 29852495
    [Abstract] [Full Text] [Related]

  • 15. Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites.
    Kida Y.
    Dig Dis; 2019 Jun 28; 37(3):239-246. PubMed ID: 30625470
    [Abstract] [Full Text] [Related]

  • 16. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S, Zhao JJ, Tong NW, Guo XH, Qiu MC, Yang GY, Liu ZM, Ma JH, Zhang ZW, Gu F.
    J Clin Pharmacol; 2014 Dec 28; 54(12):1362-7. PubMed ID: 24906029
    [Abstract] [Full Text] [Related]

  • 17. Tolvaptan for the treatment of liver cirrhosis oedema.
    Sakaida I.
    Expert Rev Gastroenterol Hepatol; 2014 Jul 28; 8(5):461-70. PubMed ID: 24678622
    [Abstract] [Full Text] [Related]

  • 18. Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites.
    Shigefuku R, Iwasa M, Eguchi A, Tempaku M, Tamai Y, Suzuki T, Takei Y.
    Intern Med; 2021 Jul 28; 60(21):3359-3368. PubMed ID: 34719623
    [Abstract] [Full Text] [Related]

  • 19. Impact of continued administration of tolvaptan on cirrhotic patients with ascites.
    Kogiso T, Sagawa T, Kodama K, Taniai M, Tokushige K.
    BMC Pharmacol Toxicol; 2018 Dec 18; 19(1):87. PubMed ID: 30563565
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
    Der-Nigoghossian C, Lesch C, Berger K.
    Pharmacotherapy; 2017 May 18; 37(5):528-534. PubMed ID: 28295447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.